Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Analysts at Oppenheimer dropped their FY2017 earnings per share estimates for Teva Pharmaceutical Industries in a research note issued to investors on Sunday. Oppenheimer analyst D. Archila now anticipates that the company will post earnings of $3.73 per share for the year, down from their previous estimate of $3.75. Oppenheimer has a “Hold” rating on the stock. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ Q4 2017 earnings at $0.74 EPS.
A number of other analysts also recently weighed in on TEVA. Wells Fargo & Co restated a “sell” rating on shares of Teva Pharmaceutical Industries in a research report on Monday. Vetr upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $22.65 target price for the company in a research report on Wednesday, January 17th. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Monday. Mizuho restated a “hold” rating and issued a $16.00 target price on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 4th. Finally, BidaskClub upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 28th. Eight investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.32.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.95 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%.
Hedge funds have recently made changes to their positions in the business. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $106,000. Bank of Nova Scotia increased its stake in shares of Teva Pharmaceutical Industries by 8.3% during the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock valued at $229,000 after buying an additional 528 shares during the period. Penserra Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $129,000. Americafirst Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $303,000. Finally, Salem Investment Counselors Inc. increased its stake in shares of Teva Pharmaceutical Industries by 12.8% during the second quarter. Salem Investment Counselors Inc. now owns 9,400 shares of the company’s stock valued at $312,000 after buying an additional 1,068 shares during the period. Hedge funds and other institutional investors own 51.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Teva Pharmaceutical Industries Ltd (TEVA) Decreased by Analyst” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/23/fy2017-eps-estimates-for-teva-pharmaceutical-industries-ltd-teva-decreased-by-analyst.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.